6
INAF0203.TXT

INAF
Indofarma Tbk
Af          :
Sector Code : 53
Sector Name : PHARMACEUTICALS

(In thousand rupiah except Par Value, Closing Price and Ratios)

Financial Statement Date    : 31-Mar-2002
Fiscal Year Ends            : Dec
Months Covered in Income St : 3

Summary of Balance Sheet
  Receivables               :     181,961,196.06
  Inventories               :     352,055,578.51
  Current Assets            :     704,890,275.53
  Fixed Assets              :     112,874,943.62
  Other Asstes              :      13,575,239.06
  Total Assets              :     841,923,646.15
  Current Liabilities       :     304,173,682.62
  Longterm Liabiities       :       4,238,498.13
  Total Liabilities         :     308,412,180.76
  Authorized                :      10,000,000.00
  Paid-up Capital           :     309,687,500.00
  Par Value                 :                100
  Paid-up Capital Shares    :       3,096,875.00
  Retained Earnings         :     142,425,762.82
  Total Equity              :     526,765,025.24
  Minority Interest         :       6,746,440.15

Summary of Income Statement
  Total Sales               :     119,074,438.31
  Cost of Good Sold         :      59,700,056.89
  Gross Profit              :      59,374,381.42
  Operating Profit          :      26,723,592.00
  Other Income              :       1,203,325.19
  Eearning Before Tax       :      27,926,917.19
  Tax                       :      11,639,569.71
  Net Income                :      15,920,562.26
  Closing Price             :             240.00

Per Share Data (Rp)
  Eps                       :              20.56
  Book Value                :             170.10

Financial Ratios
  Debt Equity Ratio (X)     :                .59
  Roa (%)                   :               7.56
  Roe (%)                   :              12.09
  Npm (%)                   :              13.37
  Opm (%)                   :              22.44

Cash Flow
  CF from Operating Activities                        :      -9,510,660.53
  CF from Investing Activities                        :      -5,747,040.40
  CF from Financing Activities                        :        -290,793.44
  Net Increase in Cash & Cash Equivalent              :     -15,548,494.37
  Cash & Cash Equivalent at The Beginning of The Year :     107,542,674.96
  Cash & Cash Equivalent at The End of The Year       :      92,482,875.19

 
 
 
